Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a ...

This week's stock market saw the S&P 500 rise 3.4%, fueled by positive inflation data and strong earnings reports.

Biogen, which developed the drug in collaboration with Sage Therapeutics, reported $27 million in sales for Zurzuvae in the first half of this year. Analysts at Jefferies have previously suggested ...

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger ...